ERBB2 and breast cancer: Hitherto, HER2-low/HR− BC is considered as HER2−/HR− in clinical practice, but this difference might reflect a dissimilar clinical behavior, and ultimately further supports the clinical investigation of new HER2-targeting agents in HER2-low BC.